PR Newswire·Sep 22, 2026, 10:42 AM ET

First patient treated with Leqembi® (lecanemab) in Sweden

BioArctic AB announced that Leqembi is now available at a private clinic in Sweden with the first patient beginning treatment on September 22, 2026.
This marks the first time a patient in Sweden has received Leqembi treatment outside of a clinical study following EU approval in April 2025.
The New Therapies Council issued a negative recommendation for Leqembi inclusion in the publicly funded healthcare system in April 2026, leading Executive Health in Stockholm to facilitate private access.
Leqembi is indicated for adults with mild cognitive impairment or mild dementia due to Alzheimer's disease who are ApoE ε4 non-carriers or heterozygotes with confirmed amyloid pathology.
The drug was developed through a collaboration between BioArctic Eisai, based on Professor Lars Lannfelt's research at Uppsala University.
BioArctic holds commercialization rights for Leqembi in the Nordic region alongside Eisai, which manages global development commercialization.
Leqembi is approved in 53 countries, with subcutaneous dosing approvals recently added in China Japan in September 2026.
BioArctic is entitled to sales milestone payments royalties on global sales without incurring development costs for the Alzheimer's treatment.
The company continues to explore other neurodegenerative diseases including Parkinson's disease ALS using its proprietary BrainTransporter™ technology.